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Changes over time in the presenting features and clinical course of patients with primary biliary cholangitis are poorly
described. We sought to describe temporal trends in patient and disease characteristics over a 44-year period across a large
international primary biliary cholangitis cohort of 4,805 patients diagnosed between 1970 and 2014, from 17 centers across
Europe and North America. Patients were divided into ﬁve cohorts according to their year of diagnosis: 1970-1979 (n 5
143), 1980-1989 (n 5 858), 1990-1999 (n 5 1,754), 2000-2009 (n 5 1,815), and 2010 (n 5 235). Age at diagnosis,
disease stage, response to ursodeoxycholic acid, and clinical outcomes were compared. Mean age at diagnosis increased
incrementally by 2-3 years per decade from 46.9 6 10.1 years in the 1970s to 57.0 6 12.1 years from 2010 onward
(P < 0.001). The female to male ratio (9:1) and antimitochondrial antibody positivity (90%) were not signiﬁcantly variable.
The proportion of patients presenting with mild biochemical disease (according to Rotterdam staging) increased from
41.3% in the 1970s to 72.2% in the 1990s (P < 0.001) and remained relatively stable thereafter. Patients with a mild histo-
logical stage at diagnosis increased from 60.4% (1970-1989) to 76.5% (1990-2014) (P < 0.001). Correspondingly, response
to ursodeoxycholic acid according to Paris-I criteria increased; 51.7% in the 1970s and 70.5% in the 1990s (P < 0.001).
Recent decades were also characterized by lower decompensation rates (18.5% in the 1970s to 5.8% in the 2000s,
P < 0.001) and higher 10-year transplant-free survival (48.4%, 68.7%, 79.7%, and 80.1% for each respective cohort;
P < 0.001). Conclusion: In recent decades, a pattern of primary biliary cholangitis presentation consistent with an older age
at diagnosis alongside reduced disease severity has been noted; the observed trends may be explained by an increase in rou-
tine testing of liver function and/or a changing environmental trigger. (HEPATOLOGY 2018;00:000-000).
Primary biliary cholangitis (PBC) is a chronicautoimmune liver disease characterized byinﬂammation and destruction of the small
intralobular bile ducts.(1-3) The disease mainly affects
middle-aged women and has a slow, progressive
course that may lead to ﬁbrosis, cirrhosis, and liver
failure requiring liver transplantation. The standard
treatment for PBC is ursodeoxycholic acid (UDCA)
as its long-term use improves liver biochemistry,
delays histological progression, and may improve
transplant-free survival.(4-6) However, up to 40% of
patients can have an inadequate response to UDCA
that is associated with reduced transplant-free
survival.(4,7-9)
Abbreviations: AMA, antimitochondrial antibody; CI, conﬁdence interval; HCC, hepatocellular carcinoma; HR, hazards ratio; IQR, interquartile
range; PBC, primary biliary cholangitis; SD, standard deviation; UDCA, ursodeoxycholic acid.
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PBC is a rare disease, with multiple studies report-
ing an increase in its incidence and prevalence in
recent years.(10-18) In a systematic review conducted
by Boonstra et al.,(12) the incidence of PBC varied
from 0.33 to 5.8 per 100,000/year, yet its temporal
trends are conﬂicting as some studies suggest an
increase,(11,12) while others do not substantiate this
ﬁnding.(19,20) The prevalence ranged from 1.91 to
40.2 per 100,000, and all investigated studies reported
an increase.(10) An increase in prevalence impacts
how PBC contributes to the health care system and
may be a result of multiple societal and disease fac-
tors. It is important to note that initial reports of an
increasing prevalence began during the off-label use
of UDCA period, which suggests that the increased
prevalence in the UDCA era may be due to prolonged
survival.(11,14,16) Correspondingly, the absolute num-
ber of liver transplantations for PBC has decreased in
Europe and the United States since the introduction
of UDCA in the early 1990s.(3,9,21-23)
In addition to epidemiological changes, the clinical
presentation of PBC has changed over the years. Whereas
most patients presented with an advanced histological
stage in earlier decades, nowadays most patients present
during an asymptomatic stage.(24,25) Therefore, the
underlying assumption that PBC, as a disease, is a static
entity may not be accurate. We used a representative large
cohort of patients with PBC to assess how disease presen-
tation and prognosis have changed over the last nearly 50
years. In doing so, we provide long-term insight into the
changing nature of PBC in clinical practice.
Patients and Methods
POPULATION AND STUDY
DESIGN
This was a retrospective study based on patient data
retrieved from the Global PBC Study Group database,
the characteristics of which have been described in
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previous publications.(26,27) The database comprises
long-term follow-up cohorts from 17 centers across
North America and Europe. UDCA-treated and non-
treated patients aged 18 with an established PBC
diagnosis from 1970 to 2014, according to internation-
ally accepted guidelines, were included in the
study.(3,28,29) Patients with either a short follow-up
(<6 months), an unknown date of important clinical
events, an overlap syndrome, or another concomitant
liver disease were excluded. Completeness and accuracy
of the database were established through visits to indi-
vidual centers. This study was conducted in accordance
with the 1975 Declaration of Helsinki. The protocol
was approved by the institutional research board of the
corresponding center and at all participating centers
per local regulations.
DATA COLLECTION
In the established database, study entry (baseline)
was the date of UDCA therapy initiation or the date
of ﬁrst visit for nontreated patients. The following
demographic and clinical data were available at study
entry: sex, date of birth, date of diagnosis, antimito-
chondrial antibody (AMA) serological status, liver his-
tology, biochemical disease stage, and UDCA therapy
(if received and dosage). In addition, the following lab-
oratory values were available at study entry and every
6-12 months until the end of follow-up: alkaline phos-
phatase, aspartate aminotransferase, alanine amino-
transferase, total bilirubin, albumin, and platelet count.
Histology was considered if the liver biopsy was com-
pleted within 24 months of diagnosis date and dichot-
omized according to Ludwig et al.’s(30) and
Scheuer’s(31) classiﬁcation, speciﬁcally as mild (stages I
and II) and advanced (stages III and IV). The Rotter-
dam criteria were used to determine patients’ biochem-
ical stage. According to these criteria, mild stage is
deﬁned as normal bilirubin and albumin, moderate
stage is deﬁned as abnormal bilirubin or albumin, and
advanced stage is deﬁned as abnormal bilirubin and
albumin.(9,32) Baseline aspartate aminotransferase/
platelet ratio index, an independent predictor of
transplant-free survival, was calculated to stratify
patients at risk of liver transplantation and death based
on a threshold of 0.54.(33) The ﬁrst occurrence of
hepatic decompensation (ascites, variceal bleeding, or
hepatic encephalopathy), hepatocellular carcinoma
(HCC), liver transplantation, or all-cause mortality
was also retrieved.
In patients who received therapy, biochemical
response to UDCA was determined according to
Barcelona, Paris-I, Rotterdam, Toronto, and Paris-II
criteria.(7-9,34,35) In addition, the GLOBE score was
compared to age-speciﬁc thresholds to determine
UDCA response.(26) Patients were considered
responders if their GLOBE score did not surpass their
age-speciﬁc threshold.
STATISTICAL ANALYSIS
Patients diagnosed between 1970 and 2014 were
divided into ﬁve cohorts according to their year of
diagnosis: 1970-1979, 1980-1989, 1990-1999, 2000-
2009, and 2010. To compare patient and disease
characteristics across the ﬁve cohorts, we conducted
chi-squared tests for categorical variables and analyses
of variance for continuous data. P < 0.05 was consid-
ered signiﬁcant for all statistical analyses. Signiﬁcant
results were further analyzed to correct for any possible
confounding variables and to assess the inﬂuence of
other explanatory variables on the outcome measure. A
multivariable logistic regression was applied to binary
outcomes, such as biochemical response to UDCA,
biochemical disease stage (moderate and advanced dis-
ease stage grouped as advanced), and histological stage
(odds ratio with 95% conﬁdence interval [CI]).
For time-to-event analyses, patients diagnosed from
2010 onward were excluded due to a shorter follow-up
period than the other cohorts. Patients without an
event and those who were lost to follow-up were cen-
sored at their last visit. The rates of hepatic decompen-
sation, HCC, and liver transplant-free survival were
assessed by Kaplan-Meier estimates and compared
across decades using the log-rank test. If decompensa-
tion occurred within the ﬁrst year of study entry, the
patient was excluded from the time-to-event analysis
for decompensation. Transplant-free survival of the
PBC population was also compared within each
decade to an age- and gender-matched Dutch popula-
tion. These outcomes were also estimated by Cox pro-
portional hazards’ modeling (hazards ratio [HR] with
95% CI).
Demographic and clinical characteristics are pre-
sented as count (percentage) for categorical data and
mean 6 standard deviation (SD) for continuous varia-
bles. Laboratory values are presented as median (inter-
quartile range [IQR]). Data that were not normally
distributed were log-transformed for the analyses. All
analyses were two-sided and were performed using
HEPATOLOGY, Vol. 00, No. 00, 2018 MURILLO PEREZ ET AL.
3
IBM SPSS Statistics for Windows, version 24.0 (IBM
Corp., Armonk, NY).
Results
STUDY POPULATION
CHARACTERISTICS
A total of 4,805 PBC patients, diagnosed between
1970 and 2014, were included and divided into ﬁve
cohorts according to their year of diagnosis (Table 1;
Supporting Table S1): 143 patients were diagnosed
from 1970 to 1979, 858 patients from 1980 to 1989,
1,754 patients from 1990 to 1999, 1,815 patients from
2000 to 2009, and 235 patients from 2010 onward.
The characteristics of each cohort are presented in
Table 1. The median follow-up times for the ﬁve
respective cohorts were 6.7 years (IQR 3.0-14.3), 8.9
years (IQR 4.0-14.7), 10.0 years (IQR 6.0-13.9), 5.6
years (IQR 3.4-8.3), and 1.6 years (IQR 1.0-2.1). The
mean time from diagnosis to study entry was variable
for each cohort: 11.1 years (SD 7.0) for the 1970s, 5.1
years (SD 4.5) for the 1980s, 1.4 years (SD 2.3) for the
1990s, 0.4 years (SD 1.1) for the 2000s, and 0.1 years
(SD 0.2) from 2010 onward. To consider this varia-
tion, all analyses were repeated in a subgroup of
patients (n 5 3,518) with a maximum 2-year lag
between diagnosis and study entry, which included
14%, 29%, 76%, 93%, and 100% of patients from the
main analysis in each respective cohort (Supporting
Table S2).
AGE AND SEX TRENDS
The mean age at diagnosis increased incrementally
from 46.9 6 10.1 years in the 1970s to 57.0 6 12.1
years from 2010 onward (P < 0.001) (Fig. 1A). This
trend was consistent across center, sex, and biochemi-
cal disease stage (Supporting Fig. S1A-C). The effect
of calendar time on the increase in age at diagnosis
remained signiﬁcant (P < 0.001) after correcting for
sex (Supporting Table S3). Furthermore, the age dis-
tribution of patients notably changed over the investi-
gated decades (P < 0.001) (Fig. 1B). The proportion
of patients aged 50-59 years at diagnosis remained
TABLE 1. Demographic and Clinical Characteristics of PBC Patients at Study Entry Over Calendar Time
Baseline
Characteristics
1970-1979
(n 5 143)
1980-1989
(n 5 858)
1990-1999
(n 5 1754)
2000-2009
(n 5 1815)
2010
(n 5 235) P
Age at diagnosis (years)* 46.9 (10.1) 50.1 (10.7) 52.8 (11.5) 55.0 (12.5) 57.0 (12.1) <0.001
Female 131 (91.6) 775 (90.3) 1,593 (90.8) 1,619 (89.2) 207 (88.1) 0.396
AMA-positive† 123/140 (87.9) 763/842 (90.6) 1,565/1,704 (91.8) 1,599/1,765 (90.6) 213/235 (90.6) 0.449
Laboratory values‡
Serum ALP (3ULN) 2.99 (1.85-4.77) 3.20 (1.95-5.23) 2.03 (1.30-3.56) 1.79 (1.19-3.05) 1.55 (1.08-2.93) <0.001
Serum bilirubin (3ULN) 0.93 (0.60-2.1) 0.81 (0.52-1.30) 0.64 (0.47-1.00) 0.60 (0.41-0.95) 0.59 (0.41-1.0) <0.001
Serum AST (3ULN) 1.59 (1.06-2.32) 1.95 (1.20-2.77) 1.35 (0.87-2.20) 1.30 (0.90-2.00) 1.29 (0.85-2.07) <0.001
Serum ALT (3ULN) 1.30 (0.85-2.47) 2.00 (1.3-3.1) 1.66 (1.03-2.68) 1.42(0.90-2.27) 1.32 (0.75-2.38) <0.001
Serum albumin (3LLN) 1.11 (0.99-1.21) 1.16 (1.06-1.26) 1.14 (1.06-1.23) 1.14 (1.06-1.23) 1.14 (1.03-1.23) 0.005
Platelet count (3109/L) 194 (127-242.5) 224 (165-275) 238 (185-289) 258 (204-311) 237 (174.5-291) <0.001
APRI (>0.54)§ 61 (76.3) 260 (69.0) 456 (52.3) 476 (47.4) 85 (54.1) <0.001
Biochemical disease stagek 121/143 627/859 985/1,755 1,073/1,816 152/235 <0.001
Mild 50/121 (41.3) 370/627 (59.0) 711/985 (72.2) 757/1,073 (70.5) 106/152 (69.7)
Moderately advanced 51/121 (42.1) 196/627 (31.3) 205/985 (20.8) 238/1,073 (22.2) 27/152 (17.8)
Advanced 20/121 (16.5) 61/627 (9.7) 69/985 (7.0) 78/1073 (7.3) 19/152 (12.5)
Histological disease stage¶ 326/1001 948/1754 943/2050 <0.001
Mild (I or II) 197 (60.4) 634 (66.9) 721 (76.5)
Advanced (III or IV) 129 (39.6) 314 (33.1) 222 (23.5)
UDCA-treated# 78/139 (56.1) 735/832 (88.3) 1,605/1,737 (92.4) 1,563/1,789 (87.4) 195/230 (84.8) <0.001
Data presented as mean (SD), n (%), or median (IQR).
*Age at diagnosis not available for one patient in 2000-2009 cohort.
†AMA status was available for 4,686 (97.5%) patients.
‡ALP, bilirubin, AST, and ALT were log-transformed prior to analyses and availability for laboratory values is as follows: ALP, 3,560
(74.1%); bilirubin, 3,595 (74.8%); AST, 3,460 (72.0%); ALT, 3,007 (62.6%); albumin, 3,039 (63.2%); platelet count, 2,769 (57.6%).
§The cutoff point for APRI >0.54 at baseline is predictive of liver transplantation or death.(33)
kBiochemical disease stage classiﬁcation according to Rotterdam criteria(9) was available in 2,958 (61.6%) patients.
¶Histological disease stage at diagnosis according to Ludwig et al.(30) and Scheuer(31) classiﬁcation was available in 2,217 (46.1%)
patients.
#UDCA therapy status was available for 4,727 patients (98.4%).
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate
aminotransferase; LLN, lower limit of normal; ULN, upper limit of normal.
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relatively stable across the years, whereas the propor-
tion of patients <50 years of age decreased and that of
patients 60 years of age increased. There was no sig-
niﬁcant temporal trend in the female to male ratio,
which remained approximately 9:1 (Table 1).
LIVER BIOCHEMISTRY AND
SEROLOGICAL STATUS
The proportion of patients who were AMA-positive
did not signiﬁcantly differ across the investigated deca-
des (Table 1). Median alkaline phosphatase and biliru-
bin values (times the upper limit of normal) at study
entry decreased, while circulating platelet counts were
noted to increase (P < 0.001), which collectively sug-
gests a less advanced disease stage. The proportion of
patients with alkaline phosphatase values <2 times the
upper limit of normal increased gradually from 30.0%
in the 1970s to 63.1% from 2010 onward (P < 0.001)
(Fig. 2A). The proportion of patients with normal
serum bilirubin concentrations also increased from
51.1% in the 1970s to 77.6% in the 1990s, after which
it remained relatively stable (P < 0.001) (Fig. 2B).
Furthermore, a reduced percentage of patients with
aspartate aminotransferase/platelet ratio index >0.54
at study entry was observed (Table 1).
TRENDS IN BIOCHEMICAL AND
HISTOLOGICAL DISEASE STAGE
There was a gradual increase in the proportion of
patients presenting with a mild biochemical disease
stage from the 1970s to 1990s and remained stable there-
after (P < 0.001) (Fig. 2C). In a multivariable logistic
regression, calendar time was a signiﬁcant predictor for
biochemical disease stage (P < 0.001) after adjusting for
sex and age at diagnosis. Earlier decades were associated
with an advanced biochemical disease stage.
Out of 2,831 patients who underwent liver biopsy at
diagnosis, 2,217 patients had histological disease stage
available and were included in a subgroup analysis that
combined cohorts due to the limited number of biop-
sies in the ﬁrst and last cohorts. There were 326 biop-
sies from 1970 through 1989, 948 biopsies from 1990
through 1999, and 943 from 2000 through 2014. The
proportion of patients with a mild histological stage
(I or II) at diagnosis increased with time (Table 1
and Fig. 2D). In a multivariable logistic regression, cal-
endar time was a signiﬁcant predictor for histological
stage after adjusting for sex and age at diagnosis (P <
0.001).
TRENDS IN UDCA RESPONSE
RATES
The proportion of patients who ever received
UDCA increased across the investigated decades (P <
0.001) (Table 1). In patients who received UDCA, the
median number of years between diagnosis and the
start of UDCA therapy decreased across the respective
cohorts (1970s to 2010): 12.6 years (IQR 10.6-
16.1), 4.4 years (IQR 2.1-8.1), 0.23 years (IQR 0.0-
2.0), 0.05 years (IQR 0.0-0.41), and 0.0 years (IQR
0.0-0.04). Additionally, the median initial dosage of
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FIG. 1. Age at diagnosis of PBC patients across different decades. (A) Mean age (6 SD) at diagnosis (dots) and estimated marginal
means (squares) obtained after adjusting for sex. (B) Distribution of age groups over calendar time.
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UDCA received by patients across the ﬁve respective
cohorts increased: 9.4 mg/kg/day (IQR 8.5-11.0), 10.0
mg/kg/day (IQR 8.7-13.7), 12.2 mg/kg/day (IQR
9.2-14.7), 13.5 mg/kg/day (IQR 11.1-15.3), and 13.3
mg/kg/day (IQR 11.1-15.1).
The proportion of UDCA responders according to
Paris-I, Toronto, Paris-II, Rotterdam, and GLOBE
score criteria increased over the investigated decades
(P < 0.001) but not that according to Barcelona crite-
ria (Fig. 3; Supporting Table S4). Importantly, this
trend remained true in patients who did not meet the
individual criteria at baseline (Supporting Table S5).
In a multivariable logistic regression, calendar time was
not a signiﬁcant predictor for UDCA response accord-
ing to Paris-I criteria (Table 2). Response was associ-
ated with an increased age at diagnosis and lower
alkaline phosphatase and bilirubin levels (P < 0.001).
Additionally, calendar time was also not a signiﬁcant
predictor for UDCA response according to Toronto,
Paris-II, Rotterdam, and GLOBE score criteria
(results not shown).
DECOMPENSATION, HCC, AND
TRANSPLANT-FREE SURVIVAL
The 10-year incidence rate of hepatic decompensa-
tion (ascites, variceal bleeding, or hepatic encephalopa-
thy, whichever came ﬁrst) decreased over time: 18.5%
in the 1970s, 13.7% in the 1980s, 8.5% in the 1990s,
and 5.8% in the 2000s (Fig. 4Ai). All pairwise com-
parisons were signiﬁcantly different, except the differ-
ence between the 1970s and 1980s cohorts (P 5 0.45).
In a multivariable Cox regression, a temporal trend of
lower decompensation risk was observed after adjusting
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FIG. 2. Study entry characteristics associated with disease severity of patients diagnosed in different decades. (A) Percentage of patients
with alkaline phosphatase above or below 2 times the upper limit of normal. (B) Percentage of patients with bilirubin above or below 1
times the upper limit of normal. (C) Percentage of patients corresponding to each biochemical stage according to Rotterdam criteria(9):
mild (normal albumin and bilirubin), moderate (abnormal albumin or bilirubin), advanced (abnormal albumin and bilirubin). (D) Percent-
age of patients corresponding to each histological stage at diagnosis according to Ludwig et al.’s(30) and Scheuer’s(31) classiﬁcations: mild
(stages I and II) or advanced (stages III and IV). Abbreviations: ALP, alkaline phosphatase; ULN, upper limit of normal.
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for sex and age at diagnosis (Fig. 4Bi) (P 5 0.07).
Calendar time as a continuous variable was a signiﬁ-
cant predictor for hepatic decompensation (HR, per
10-year increase, 0.57; 95% CI 0.44-0.75; P < 0.001).
The 10-year HCC incidence rates across the investi-
gated decades were 10.3%, 4.0%, 2.1%, and 2.3%,
respectively (Fig. 4Aii). The Kaplan-Meier estimate of
cumulative HCC incidence was signiﬁcantly higher in
the 1970s compared to the 1980s (P 5 0.01), 1990s
(P < 0.001), and 2000s (P < 0.001). In a multivariable
Cox regression, calendar time was not a signiﬁcant
predictor for HCC risk (P 5 0.68) after adjusting
for sex, age at diagnosis, and UDCA treatment
(Fig. 4Bii).
The 10-year liver-related death rate decreased from
1970 through 2009: 34.6%, 13.2%, 5.6%, and 6.4%
(P < 0.001). Furthermore, the 10-year transplant-free
survival rate improved over the four respective investi-
gated decades: 48.4%, 68.7%, 79.7%, and 80.1% (Fig.
4Aiii). There was a signiﬁcant difference in transplant-
free survival between the 1970s and 1980s (P < 0.001)
and between the 1980s and 1990s (P < 0.001). How-
ever, the transplant-free survival rates between the 1990s
and 2000s were equivalent (P5 0.80). In a multivariable
Cox regression, calendar time remained an independent
predictor of transplant-free survival, and earlier decades
were associated with an increased risk for liver transplan-
tation and all-cause mortality (Fig. 4Biii; Supporting
Table S6). Furthermore, the 10-year transplant-free sur-
vival of PBC patients has improved even when
compared to an age- and gender-matched general popu-
lation (1970s: HR 5 4.38; 95% CI 3.54-5.43; P <
0.001; 1980s: HR 5 2.90; 95% CI 2.60-3.24;
P < 0.001; 1990s: HR 5 2.14; 95% CI 1.94-2.36; P <
0.001; 2000s: HR 5 1.93; 95% CI 1.69-2.21; P <
0.001).
Discussion
In this study of a large, internationally representative
cohort of PBC patients, we demonstrate that patients
diagnosed in recent decades are older and have a
milder disease stage compared to patients diagnosed in
earlier decades. In addition, more patients respond
favorably to UDCA therapy and have improved
transplant-free survival. These results provide unique
insight into the possible changing natural history of
PBC over the last ﬁve decades. It is noteworthy to
mention that similar results have been observed in a
study from Sweden that included 246 patients diag-
nosed with primary sclerosing cholangitis between
1984 and 2004. Bergquist et al. reported an increase in
age at diagnosis and lower frequency of symptoms in
patients diagnosed after 1998.(36)
Although some of the observed trends could be
potentially attributed to more sensitive AMA tests that
TABLE 2. Multivariable Logistic Regression for the
Attainment of Biochemical Response According to Paris-I*
(n 5 2,283)
Variable OR 95% CI P
Male sex 0.90 0.63-1.29 0.58
Year of diagnosis 0.67
1970-1979 1.00
1980-1989 0.80 0.37-1.71 0.66
1990-1999 1.01 0.44-2.37 0.96
2000-2009 0.97 0.40-2.32 0.94
2010 0.92 0.33-2.57 0.88
Age at diagnosis (years) 0.04
<30 1.00
30-39 1.29 0.53-3.15 0.57
40-49 1.41 0.60-3.33 0.44
50-59 1.95 0.82-4.59 0.13
60-69 2.06 0.86-4.96 0.11
70 2.06 0.82-5.21 0.13
Log bilirubin (3ULN) 0.01 0.01-0.02 <0.001
Log ALP (3ULN) 0.12 0.08-0.18 <0.001
Difference between diagnosis
and study entry (years)
0.98 0.94-1.03 0.44
*Response rate according to Paris-I is deﬁned as ALP 3
3ULN, AST 2 3ULN, and normal bilirubin after 1 year of
UDCA therapy.
ALP, alkaline phosphatase; OR, odds ratio; ULN, upper limit of
normal.
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FIG. 3. Response rates to UDCA therapy over calendar time.
Response was determined according to various published criteria:
Barcelona, Paris-I, Rotterdam, Toronto, Paris-II, and the
GLOBE score.(7-9,26,34,35) Response rates according to all criteria
were signiﬁcantly different over calendar time (P < 0.001), except
for Barcelona criteria (P 5 0.19).
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FIG. 4. Time-to-event analyses of decompensation, HCC, and liver transplantation or death over calendar time. (A) Kaplan-Meier
(crude) and (B) Multivariable Cox regression (adjusted) estimates of (i) cumulative incidence of decompensation, (ii) cumulative
incidence of HCC, and (iii) transplant-free survival.
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detect the disease at an earlier stage, we speculate
that any changes in AMA testing have not had a
major impact in the observed temporal trends. The
conventional method of AMA detection is indirect
immunoﬂuorescence, yet there has been an increase in
enzyme-linked immunosorbent assay–based assays and
immunoblotting that have led to greater sensitivity and
speciﬁcity.(37) These improvements would translate to
an increase in the proportion of AMA-positive patients;
however, this has remained unchanged.
We demonstrate a 10-year increase in the mean age
at diagnosis from 1970 to 2014. A similar increase was
reported in a Canadian PBC population, in which
prevalent cases in 1996 had a median age of 53,
whereas prevalent cases in 2002 had a median age of
57.(18) These numbers coincide with the ﬁndings from
our study, in which the mean ages at diagnosis in the
1990s and 2000s are 52.8 and 55.0 years, respectively.
Furthermore, an increased proportion of patients diag-
nosed in recent years are over 50 years of age and
account for 71.5% of patients diagnosed on 2010 and
beyond. Comparable results were found within the
UK-PBC cohort, in which 75% of patients prevalent
between 2008 and 2010 were over 50 years of age.(38)
The increase in age may be attributed to the general
aging of the population as the median age in North
America and Europe has reportedly increased from 30
in 1970 to 40 in 2015.(39) This represents a 10-year
increase over a 45-year period, which is similar to the
10-year increase in age at diagnosis we observed over a
44-year interval. Furthermore, the 34% absolute
increase of PBC patients 50 years old and above from
1970 to 2014 was greater than that of the general pop-
ulation, which was only 11% (25% in 1970 to 36% in
2015).(39) The increase in age may also be attributed to
differences in the trigger for a PBC diagnosis over the
years. Although we are not able to assess the symptoms
in our cohort, we speculate that patients in recent deca-
des are predominantly asymptomatic and are therefore
diagnosed when they see their physician to undergo
routine testing of liver function, which occurs more
frequently in older individuals. Conversely, younger
patients in earlier decades were more likely to develop
symptoms, which led to their diagnoses.(40,41) Lastly,
the increase in age may be disease-speciﬁc and repre-
sents a shift in the natural history of PBC toward a
new older at-risk population, considering that the
increase in age was observed irrespective of biochemical
disease stage. It can also be speculated that the later
onset is a result of a prolonged subclinical disease
period and potentially a delayed exposure to an
unknown environmental trigger due to temporal
changes in lifestyle.
An older age at diagnosis is clinically important
because it has been associated with an increased likeli-
hood of meeting Paris-I criteria for response to
UDCA.(38) Similarly, we found an older age at diagno-
sis to be an independent predictor of Paris-I response,
yet calendar time was not a signiﬁcant predictor. These
results indicate the increase in age at diagnosis may be
an important factor contributing to the increase in
UDCA response rather than calendar time itself. Fur-
thermore, the low response rates observed in earlier
decades can be a result of inadequate UDCA dosages
and the delay in treatment. The importance of an ade-
quate UDCA dosage of 13-15 mg/kg/day has been
emphasized in a study that found that 40% of UDCA
nonresponders in whom the dosage was increased
became responders.(42,43)
In recent decades, Patients present at an older age,
yet they have a milder biochemical and histological dis-
ease stage. Improved disease severity might be
explained by an earlier detection of PBC due to
improved disease awareness leading to liver function
tests and AMA assays.(44,45) The histological disease
stage at diagnosis has important prognostic implica-
tions for UDCA response and survival. Advanced his-
tological stages are associated with an increased risk of
treatment failure.(8) In addition, the survival of
UDCA-treated patients in stage I/II is similar to that
of an age- and sex-matched control population, while
the probability of liver transplantation or death is sig-
niﬁcantly increased in patients with advanced histolog-
ical stages.(46)
Although a decrease in the number of liver trans-
plantations for PBC has been reported over the
years,(22) an improvement in transplant-free survival
has not been documented. In a Canadian
population-based study of patients diagnosed
between 1996 and 2002, Myers et al. did not observe
a signiﬁcant difference in survival according to year
of diagnosis.(18) The lack of difference in survival
may be attributed to the small interval of study,
which only spanned 6 years. The reported increase in
median age of the general population well reﬂects an
increase in life expectancy over time(39); therefore,
transplant-free survival of PBC patients was com-
pared to that of the general population. Our study
showed that transplant-free survival improved over a
44-year period, even when compared to the general
population, and supports its potential role in the
increased prevalence of PBC.
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The inclusion of a large population of PBC patients
from different geographical regions, long-term follow-
up, and broad study period are some of the strengths
of our study. However, some limitations need to be
considered. First, the 1970s and 1980s cohorts were
susceptible to a delay in documentation since study
entry can be many years after the date of diagnosis in
these cohorts. As such, the difference in years between
these two dates was included in all multivariable analy-
ses and we assessed a subgroup of patients with a maxi-
mum 2-year difference. The same trends emerged in
the subgroup analyses, thus excluding the possibility
that the delay in documentation is the reason for an
advanced disease in the early cohorts. Second, due to
the retrospective nature of the study, biochemical data
were not available for all patients and, thus, response to
UDCA could not be determined for all patients. To
account for missing laboratory values, all analyses were
repeated in an imputed data set and revealed similar
results. Lastly, the trends observed in our study cohort
could not be assessed for correlations with symptom
proﬁles or various environmental factors previously
associated with PBC, such as smoking, age at ﬁrst
pregnancy, and the use of hormonal replacement ther-
apy.(47) Even though the trends observed may be due
to a selection of patients whose diagnosis is triggered
by symptoms or complications in earlier decades rather
than routine liver function tests as in recent decades,
we describe the presenting characteristics of a typical
PBC patient seen by physicians and how they have
changed over time. The observed temporal trends war-
rant further investigation in other PBC populations to
determine whether they are universally applicable and
to explore the potential inﬂuence of a changing envi-
ronmental trigger.
In conclusion, we demonstrate a 10-year increase in
age at diagnosis accompanied by milder disease severity
at presentation of PBC patients. These ﬁndings pro-
vide the most comprehensive evidence of a changing
natural history of PBC to date.
REFERENCES
1) Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J
Med 2005;353:1261-1273.
2) Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol
2010;52:745-758.
3) Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV,
Heathcote EJ. Primary biliary cirrhosis. HEPATOLOGY 2009;50:
291-308.
4) Pratt DS. Primary biliary cholangitis—a new name and a new
treatment. N Engl J Med 2016;375:685-687.
5) Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER,
Poupon R, Heathcote EJ. Combined analysis of randomized
controlled trials of ursodeoxycholic acid in primary biliary cirrho-
sis. Gastroenterology 1997;113:884-890.
6) Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary
cirrhosis: incidence and predictive factors of cirrhosis develop-
ment in ursodiol-treated patients. Gastroenterology 2002;122:
652-658.
7) Pares A, Caballerıa L, Rodes J. Excellent long-term survival in
patients with primary biliary cirrhosis and biochemical response
to ursodeoxycholic acid. Gastroenterology 2006;130:715-720.
8) Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T,
Johanet C, et al. Biochemical response to ursodeoxycholic acid
and long-term prognosis in primary biliary cirrhosis. HEPATOLOGY
2008;48:871-877.
9) Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW,
Van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of
patients with primary biliary cirrhosis that have a biochemical
response to ursodeoxycholic acid. Gastroenterology 2009;136:
1281-1287.
10) Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary
sclerosing cholangitis and primary biliary cirrhosis: a systematic
review. J Hepatol 2012;56:1181-1188.
11) Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence
and prevalence of primary biliary cirrhosis in the city of Newcas-
tle upon Tyne, England. Int J Epidemiol 1997;26:830-836.
12) Boonstra K, Kunst AE, Stadhouders PH, Tuynman HA, Poen
AC, van Nieuwkerk KM, et al. Rising incidence and prevalence
of primary biliary cirrhosis: a large population-based study. Liver
Int 2014;34:e31-e38.
13) Eriksson S, Lindgren S. The prevalence and clinical spectrum of
primary biliary cirrhosis in a deﬁned population. Scand J Gastro-
enterol 1984;19:971-976.
14) Myszor M, James OF. The epidemiology of primary biliary cir-
rhosis in north-east England: an increasingly common disease? Q
J Med 1990;75:377-385.
15) Remmel T, Remmel H, Uibo R, Salupere V. Primary biliary cir-
rhosis in Estonia. With special reference to incidence, prevalence,
clinical features, and outcome. Scand J Gastroenterol 1995;30:
367-371.
16) James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV.
Primary biliary cirrhosis once rare, now common in the United
Kingdom? HEPATOLOGY 1999;30:390-394.
17) Pla X, Vergara M, Gil M, Dalmau B, Cistero B, Bella RM,
et al. Incidence, prevalence and clinical course of primary biliary
cirrhosis in a Spanish community. Eur J Gastroenterol Hepatol
2007;19:859-864.
18) Myers RP, Shaheen AA, Fong A, Burak KW, Wan A, Swain
MG, et al. Epidemiology and natural history of primary biliary
cirrhosis in a Canadian health region: a population-based study.
HEPATOLOGY 2009;50:1884-1892.
19) McNally RJ, James PW, Ducker S, Norman PD, James OF. No
rise in incidence but geographical heterogeneity in the occurrence
of primary biliary cirrhosis in north east England. Am J Epide-
miol 2014;179:492-498.
20) Baldursdottir TR, Bergmann OM, Jonasson JG, Ludviksson BR,
Axelsson TA, Bj€ornsson ES. The epidemiology and natural his-
tory of primary biliary cirrhosis: a nationwide population-based
study. Eur J Gastroenterol Hepatol 2012;24:824-830.
MURILLO PEREZ ET AL. HEPATOLOGY, Month 2018
10
21) Gross RG, Odin JA. Recent advances in the epidemiology of
primary biliary cirrhosis. Clin Liver Dis 2008;12:289-303.
22) Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N.
Transplantation trends in primary biliary cirrhosis. Clin Gastro-
enterol Hepatol 2007;5:1313-1315.
23) Hirschﬁeld GM, Mason A, Luketic V, Lindor K, Gordon SC,
Mayo M, et al. Efﬁcacy of obeticholic acid in patients with pri-
mary biliary cirrhosis and inadequate response to ursodeoxycholic
acid. Gastroenterology 2015;148:751-761.
24) Christensen E, Crowe J, Doniach D, Popper H, Ranek L,
Rodes J, et al. Clinical pattern and course of disease in primary
biliary cirrhosis based on an analysis of 236 patients. Gastroen-
terology 1980;78:236-246.
25) Locke GR 3rd, Therneau TM, Ludwig J, Dickson ER, Lindor
KD. Time course of histological progression in primary biliary
cirrhosis. HEPATOLOGY 1996;23:52-56.
26) Lammers WJ, Hirschﬁeld GM, Corpechot C, Nevens F, Lindor
KD, Janssen HL, et al. Development and validation of a scoring
system to predict outcomes of patients with primary biliary cir-
rhosis receiving ursodeoxycholic acid therapy. Gastroenterology
2015;149:1804-1812.
27) Lammers WJ, Van Buuren HR, Hirschﬁeld GM, Janssen HL,
Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase
and bilirubin are surrogate end points of outcomes of patients
with primary biliary cirrhosis: an international follow-up study.
Gastroenterology 2014;147:1338-1349.
28) Nguyen DL, Juran BD, Lazaridis KN. Primary biliary cirrhosis.
Best Pract Res Clin Gastroenterol 2010;24:647-654.
29) European Association for the Study of the Liver. EASL clinical
practice guidelines: the diagnosis and management of patients
with primary biliary cholangitis. J Hepatol 2017;67:145-172.
30) Ludwig J, Dickson ER, McDonald GA. Staging of chronic
nonsuppurative destructive cholangitis (syndrome of primary bili-
ary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:
103-112.
31) Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967;60:
1257-1260.
32) Ter Borg PC, Schalm SW, Hansen BE, Van Buuren HR. Prog-
nosis of ursodeoxycholic acid–treated patients with primary biliary
cirrhosis. Results of a 10-yr cohort study involving 297 patients.
Am J Gastroenterol 2006;101:2044-2050.
33) Trivedi PJ, Bruns T, Cheung A, Li KK, Kittler C, Kumagi T,
et al. Optimising risk stratiﬁcation in primary biliary cirrhosis:
AST/platelet ratio index predicts outcome independent of urso-
deoxycholic acid response. J Hepatol 2014;60:1249-1258.
34) Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R,
Coltescu C, et al. Baseline ductopenia and treatment response
predict long-term histological progression in primary biliary cir-
rhosis. Am J Gastroenterol 2010;105:2186-2194.
35) Corpechot C, Chazouille`res O, Poupon R. Early primary biliary
cirrhosis: biochemical response to treatment and prediction of
long-term outcome. J Hepatol 2011;55:1361-1367.
36) Bergquist A, Said K, Broome U. Changes over a 20-year period
in the clinical presentation of primary sclerosing cholangitis in
Sweden. Scand J Gastroenterol 2007;42:88-93.
37) Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA,
Coppel RL, et al. A sensitive bead assay for antimitochondrial
antibodies: chipping away at AMA-negative primary biliary cir-
rhosis. HEPATOLOGY 2007;45:659-665.
38) Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL,
Heneghan MA, et al. Sex and age are determinants of the clini-
cal phenotype of primary biliary cirrhosis and response to urso-
deoxycholic acid. Gastroenterology 2013;144:560-569.
39) United Nations. World population prospects: the 2017 revision.
https://esa.un.org/unpd/wpp/Publications/Files/WPP2017_Key-
Findings.pdf.
40) Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: sur-
vival of a large cohort of symptomatic and asymptomatic patients
followed for 24 years. J Hepatol 1994;20:707-713.
41) Prince M, Chetwynd A, Newman W, Metcalf JV, James OF.
Survival and symptom progression in a geographically based
cohort of patients with primary biliary cirrhosis: follow-up for up
to 28 years. Gastroenterology 2002;123:1044-1051.
42) Lammers WJ, Leeman M, Ponsioen CI, Boonstra K, van
Erpecum KJ, Wolfhagen FH, et al. How the concept of bio-
chemical response inﬂuenced the management of primary biliary
cholangitis over time. Neth J Med 2016;74:240-246.
43) Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C,
DeSotel CK, et al. Comparison of three doses of ursodeoxycholic
acid in the treatment of primary biliary cirrhosis: a randomized
trial. J Hepatol 1999;30:830-835.
44) Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF.
Asymptomatic primary biliary cirrhosis: clinical features, progno-
sis, and symptom progression in a large population based cohort.
Gut 2004;53:865-870.
45) European Association for the Study of the Liver. EASL clinical
practice guidelines: management of cholestatic liver diseases.
J Hepatol 2009;51:237-267.
46) Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE,
Poupon R. The effect of ursodeoxycholic acid therapy on the
natural course of primary biliary cirrhosis. Gastroenterology 2005;
128:297-303.
47) Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M,
Utts J, et al. Risk factors and comorbidities in primary biliary
cirrhosis: a controlled interview-based study of 1032 patients.
HEPATOLOGY 2005;42:1194-1202.
Author names in bold designate shared co-ﬁrst authorship.
Supporting Information
Additional Supporting Information may be found at
onlinelibrary.wiley.com/doi/10.1002/hep.29717/suppinfo.
HEPATOLOGY, Vol. 00, No. 00, 2018 MURILLO PEREZ ET AL.
11
